<DOC>
	<DOCNO>NCT01005576</DOCNO>
	<brief_summary>This study do determine blood cell transplant , either bone marrow cord blood unrelated donor , effective child severe thalassemia treatment approach acceptable risk side effect . This study include preparative regimen Hydroxyurea , Alemtuzumab , Fludarabine , Thiotepa Melphalan provide intense host immunosuppression without myeloablation . The primary hypothesis regimen promote stable engraftment unrelated donor hematopoietic cell , support normal erythropoiesis , result event free survival &gt; 75 % child thalassemia major .</brief_summary>
	<brief_title>Reduced Intensity Transplant Conditioning Regimen Severe Thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>116.00 year old Have transfusion dependent thalassemia major Shall HLAmatched family donor Must suitably match unrelated marrow donor UCB product Lansky score &gt; /= 70 Adequate pulmonary , renal , liver , organ function define protocol Negative pregnancy test Adequate total nucleate cell CD34+ dose product define protocol Iron chelation must discontinue &gt; /= 48 hour prior condition regimen Pregnant breastfeed HIV positive Prior allogeneic marrow stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Thalassemia</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Hematopoietic cell transplant</keyword>
	<keyword>non-myeloablative</keyword>
</DOC>